<DOC>
	<DOCNO>NCT01912495</DOCNO>
	<brief_summary>Prospective open label proof concept feasibility interventional clinical trial 60 acute HCV genotype 1 patient co-infected HIV receive 12 week boceprevir addition Standard Of Care Peginterferon + Ribavirin show Rapid Viral Responds week 4 . The primary hypothesis study subset patient Rapid Viral Responds 4 week triple therapy boceprevir , peginterferon alpha-2b ( P ) ribavirin ( RVR4 ) successfully treat short 12-week triple therapy regimen .</brief_summary>
	<brief_title>Dutch Acute HCV HIV Study ( DAHHS )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>1 . Documented recent HCV genotype 1 infection ( ≤26 week old time baseline visit ) accord definition mention . 2 . Plan start Standard Of Care therapy acute HCV consist 24 week Peginterferon + Ribavirin . HCV RNA plasma viral load screen &gt; 1000 IU/ml . 3 . A previously perform HCV RNA plasma measurement use screen &lt; 4 week old . 4 . On HAART time screen . 5 . Minimum age 18 year . 1 . Disallowed comedication stop replace : Several potentially lifethreatening drugdrug interaction ( DDI ) possible boceprevir combine drug . Therefore ALL comedication , include overthecounter drug check potential DDI DDI table Dutch summary product characteristic ( SPC , appendix A ) . If comedication mention SPC DDI table , www.HCVdruginteractions.org use . 2 . Contraindications use full dose peginterferon alpha2b ribavirin : neutrophil &lt; 0,75×109/l thrombocyte &lt; 100.000×109/l Hb &lt; 6.2mmol/L , creatinine clearance &lt; 50ml/min ) . 3 . History liver cirrhosis &gt; F1 fibrosis fibroscan . Inclusion patient chronic wellcontrolled HBV ( HBVDNA limit detection ) tenofovir , lamivudine emtricitabine therapy allow fibroscan excludes &gt; F1 fibrosis . Fibroscan report &lt; 2 year old use screening . Fibroscan required patient screen . 4 . HAART start &lt; 4 week baseline visit . 5 . Inability switch HAART regimen consist 2 nucleoside/tide reverse transcriptase inhibitor + Raltegravir ( Isentress® ) 400mg BID rilpivirine 25mg QD atazanavir ( Reyataz® ) 300mg QD + ritonavir ( Norvir® ) 100mg QD . 6 . Patient virologically fail HAART past</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>